They have destroyed investors value with Years of false starts and major failures. Very risky because with these non communicators you never know what’s next?????
That said, have they finally gotten it together?
Follow the recent aggressive trail...
look at it with a hawk eye..hmm
1—-RS done.
2—-Right after the RS they announced a
New patent with added subject matter.
3—-6 mths after RS suddenly there’s large dilution
(clinical trials funding?)
After the RS came this PR. I know it’s all been said before, but... well i have no reason to believe it this time either. Except.... I’m lead to believe that the added
“subject matter” was the missing ingredient that hinder them from previously moving forward. And with that one hinderance there were no guarantees and it’s possible that they were double minded about proceeding with this lingering uncertainty???? Is it ready now? Was the missing subject matter the key? We shall see.....
“Clinical trials for Pancreatic Cancer indication are currently being planned to be conducted at the McGill University Hospital “
For Immediate Release February 4, 2019
SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a ANTICANCER DRUG UNTIL 2033
Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC Markets: “SBFMD”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of cancer today announced that it has received a “Notice of Allowance” from the United States Patent and Trademark Office for a new patent application covering Adva-27a, the Company’s lead anticancer compound. The new patent (US Patent Application Number 20150353573) contains new subject matter and extends the proprietary protection of Adva-27a until 2033. Sunshine Biopharma is the sole owner of all existing intellectual property rights and patents pertaining to Adva-27a, including US Patent Number 8,236,935 issued in 2012.
“We are very excited about this significant development for Adva-27a,” said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. “Allowance of the second Adva-27a patent application gives us 14 years of additional protection and is a validation of the unique and innovative aspects of our anticancer molecule,” he added.
Adva-27a is Sunshine Biopharma’s proprietary anticancer compound. Tests conducted on Adva-27a have demonstrated the drug’s effectiveness at destroying Multidrug Resistant Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are currently being planned to be conducted at the McGill University Hospital Centers in Montreal, Canada.
High risk INDEED!!!!!!
But do they have the cure for cancer with this new patent?
How big could that be?
Hmm just my thoughts:-)
News 
Market Data 
Discover 
